2nd Quarter - Report

INFUSION PROVIDERS ALLIANCE for INFUSION PROVIDERS ALLIANCE

Firm
Client
Income
—
Expenses
$27,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Implementation of provisions included in Subtitle B of PL. 117-169 - Inflation Reduction Act of 2022. Issues related to downcoding of certain complex Part B drugs by regional Medicare Administrative Contractors (MACs). Support for site neutrality policies including in H.R. 3561 - the Promoting Access to Treatments and Increasing Extremely Needed Transparency Act of 2023 or the PATIENT Act of 2023. Advocating for access to biosimilars. HR 5391/S. 2764, Protecting Patient Access to Cancer and Complex Therapies Act. S. 652/HR 2630, Safe Step Act. S. 1375/HR 830, HELP Copays Act. Issues related to white bagging. Access to Alzheimer's Disease therapies. Issues related to virtual supervision of infusion drugs. Advocating for access to biosimilars. Access to Alzheimer's Disease therapies.

LobbyistCovered position, as disclosed
BRAD TRAVERSE New Former Senior Advisor, Office of the HHS Assistant Secretary of Public Affairs

Contacted: HOUSE OF REPRESENTATIVES; SENATE; Centers For Medicare and Medicaid Services (CMS); Medicare Payment Advisory Commission (MedPAC)

Bills named: S. 652 (118th), H.R. 3561 (118th), H.R. 2630 (118th), H.R. 5391 (118th), S. 2764 (118th), H.R. 830 (118th), S. 1375 (118th)

Health Issues HCR

Issues related to the Change Healthcare cyber-attack.

LobbyistCovered position, as disclosed
BRAD TRAVERSE —

Contacted: SENATE; Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.